Array Biopharma Inc news

   Watch this stock
Showing stories 1 - 10 of about 84   

Articles published

ARRY 4.82 -0.04 (-0.82%)
price chart
Why Array Biopharma Inc. Stock Roared Higher
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Why Array Biopharma (ARRY) Stock Surged Yesterday  Bidness ETC
Why Delta Air Lines, Hawaiian Electric Industries, and Array BioPharma are 3 ...  Investorplace.com
Related articles »  
Biotech Stocks Technical Report -- Achillion Pharma, Arrowhead Research ...
Although Array BioPharma Inc.'s stock has advanced 5.88% in the previous three trading sessions and 29.26% in the last one month, it has fallen by 2.99% on YTD basis.
Related articles »  
Array BioPharma, Inc. (ARRY) in Focus: Stock Soars 14.3%
Array BioPharma, Inc. (ARRY - Snapshot Report) was a big mover last session, as the company saw its shares rise by over 14% on the day.
Related articles »  
BUZZ-Array BioPharma Inc: Eight-month high on Novartis deal
Says late Wednesday Swiss drugmaker Novartis AG returned rights to experimental cancer drug and agreed to pay $85 mln upfront. ** Deal with Novartis is economically favorable to Array, allowing the smaller drug developer to conserve cash to develop ...
Company Short Term Price Targets: Array Biopharma Inc , Pitney Bowes Inc
Array Biopharma Inc (NASDAQ:ARRY): The stock price is expected to reach $ 7.5 in the short term. The number of analysts agreeing with this consensus is 6. The higher estimate for the short term price target is at $9 while the lower estimate is at $6.
Related articles »  
Array BioPharma to regain global rights to cancer therapy
Array BioPharma (NASDAQ:ARRY) +24% AH says it reached a deal with Novartis (NYSE:NVS) to regain global rights to its binimetinib cancer treatment as well as an upfront payment of $85M.
Premarket Movers, December 4: Array Biopharma Inc (NASDAQ:ARRY), Kindred ...
Array Biopharma Inc (NASDAQ:ARRY), +23.79%, on today's news that the company will regain Binimetinib rights from Novartis AG (ADR) (NYSE:NVS).
Benzinga's Top #PreMarket Gainers  Benzinga
Pre-market Gainers: Array BioPharma (NASDAQ:ARRY), The Kroger Co. (NYSE ...  Property Mentor
Related articles »  
Boulder's Array BioPharma to regain rights to cancer drug binimetinib
Boulder-based Array BioPharma Inc. has announced that it has reached an agreement with Novartis International Pharmaceutical Ltd.
Pharma Stocks To Look Out For: Kindred Biosciences (KIN), Ariad ...
Array Biopharma Inc (NASDAQ:ARRY) announced yesterday that it will regain rights to its cancer drug candidate, binimetinib, from Novartis AG (ADR) (NYSE:NVS).
Related articles »  
Oncothyreon secures exclusive license to HER2 inhibitor
Array bioPharma (ARRY +0.8%) grants Oncothyreon (ONTY +5.3%) an exclusive license to develop, manufacture and commercialize the HER2 inhibitor ONT-380 (ARRY-380). The license replaces the co-development contract between the two firms.
Oncothyreon Announces Exclusive License Agreement With Array BioPharma ...  MarketWatch
Related articles »